Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
July 10, 2023 08:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
May 18, 2023 06:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented...
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
May 09, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease...
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
May 09, 2023 06:55 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023 16:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast
May 02, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference
March 28, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
March 07, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
- Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis - -...
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
March 06, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement...